FY2029 Earnings Forecast for XENE Issued By Wedbush

Xenon Pharmaceuticals Inc. (NASDAQ:XENEFree Report) – Equities research analysts at Wedbush issued their FY2029 EPS estimates for Xenon Pharmaceuticals in a research note issued to investors on Thursday, January 23rd. Wedbush analyst L. Chico anticipates that the biopharmaceutical company will post earnings per share of $5.54 for the year. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Raymond James reiterated an “outperform” rating and issued a $50.00 price target on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $56.00.

Get Our Latest Analysis on XENE

Xenon Pharmaceuticals Trading Down 0.1 %

Shares of XENE stock opened at $39.95 on Friday. Xenon Pharmaceuticals has a 12-month low of $35.53 and a 12-month high of $50.99. The firm’s 50 day moving average is $40.20 and its 200 day moving average is $40.82. The stock has a market capitalization of $3.05 billion, a P/E ratio of -14.17 and a beta of 1.20.

Xenon Pharmaceuticals (NASDAQ:XENEGet Free Report) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same quarter in the previous year, the firm posted ($0.73) earnings per share.

Insider Activity at Xenon Pharmaceuticals

In related news, Director Gary Patou sold 4,891 shares of Xenon Pharmaceuticals stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total transaction of $200,922.28. Following the transaction, the director now owns 23,573 shares in the company, valued at approximately $968,378.84. The trade was a 17.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sherry Aulin sold 18,709 shares of Xenon Pharmaceuticals stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. 5.52% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of XENE. Loomis Sayles & Co. L P lifted its stake in Xenon Pharmaceuticals by 7.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 707,222 shares of the biopharmaceutical company’s stock worth $27,843,000 after purchasing an additional 46,964 shares in the last quarter. Vestal Point Capital LP lifted its stake in Xenon Pharmaceuticals by 57.1% in the 3rd quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company’s stock worth $32,480,000 after purchasing an additional 300,000 shares in the last quarter. Driehaus Capital Management LLC lifted its stake in Xenon Pharmaceuticals by 2.3% in the 2nd quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company’s stock worth $172,315,000 after purchasing an additional 97,732 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in Xenon Pharmaceuticals by 4.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 439,074 shares of the biopharmaceutical company’s stock worth $17,287,000 after purchasing an additional 17,953 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Xenon Pharmaceuticals by 1,263.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock worth $38,456,000 after purchasing an additional 905,129 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

(Get Free Report)

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

Further Reading

Earnings History and Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.